FDA Cancels Licence of Ayurvedic Firm Inducare Pharma Pvt Ltd
The Food and Drug Administration (FDA) has cancelled the manufacturing license of Inducare Pharma Pvt Ltd at Jejuri in Pune due to serious irregularities found during the inspection.
Intelligence analysis by Llama
The FDA has cancelled the manufacturing license of Inducare Pharma Pvt Ltd at Jejuri in Pune due to serious irregularities found during the inspection. The irregularities included a lack of cleanliness in the production department, suction filters not being cleaned, and basic quality management systems such as pest control and packaging material records being absent.
The FDA cancelled the licence of a medicine company because they found that the company was not making medicines properly. They found that the company was not cleaning the machines, and the medicines were not good quality. This is to protect people from taking bad medicines.
Analysis
Irregularities Found During Inspection
The FDA officials found serious irregularities during the inspection of Inducare Pharma Pvt Ltd at Jejuri in Pune. The irregularities included a lack of cleanliness in the production department, suction filters not being cleaned, and basic quality management systems such as pest control and packaging material records being absent. This is a serious concern as it can lead to the production of substandard medicines that can harm consumers.
Samples of Medicines Declared Not of Standard Quality
Samples of medicines manufactured by the firm were declared not of standard quality and serious deficiencies were detected during the tests. The medicines included Sinhanad Guggul, Punarnavadi Mandur, Triphala Guggul, Knchanar Guggul, Hingvastak Churna, and Triphala Churna. The products failed the prescribed Microbial Limit Test and contained fungal growth, black spots, insects, and larvae.
Permanent Cancellation of Licence
After a detailed examination of the inspection reports, laboratory findings, show-cause proceedings, submissions made during the personal hearing, and other relevant records, the competent licensing authority ordered the permanent cancellation of the Ayurvedic drug manufacturing licence. This is a stern move by the FDA to ensure that manufacturers adhere to the Drugs and Cosmetics Act, 1940 and Good Manufacturing Practice (GMP) standards.
Key points
- The FDA has cancelled the manufacturing license of Inducare Pharma Pvt Ltd at Jejuri in Pune due to serious irregularities found during the inspection.
- The irregularities included a lack of cleanliness in the production department, suction filters not being cleaned, and basic quality management systems such as pest control and packaging material records being absent.
- Samples of medicines manufactured by the firm were declared not of standard quality and serious deficiencies were detected during the tests.
- The competent licensing authority ordered the permanent cancellation of the Ayurvedic drug manufacturing licence.
The cancellation of the manufacturing license of Inducare Pharma Pvt Ltd is a positive step towards ensuring the quality of medicines. It shows that the FDA is taking strict action against manufacturers who do not adhere to the Drugs and Cosmetics Act, 1940 and Good Manufacturing Practice (GMP) standards.
The cancellation of the manufacturing license of Inducare Pharma Pvt Ltd may lead to job losses and financial difficulties for the employees and owners of the company. It may also lead to a shortage of medicines in the market, which can be a concern for consumers.
